Table 1.
Demographics, Presenting Symptoms, Parameters, and Laboratory Investigations Stratified by Remdesivir treatment.
| Remdesivir | No Remdesivir | P-value | ||
|---|---|---|---|---|
| N | 28 | 27 | ||
| Age, years | 55 (45-65) | 55 (42-65) | 0.83 | |
| Sex | 26 (93%) | 16 (59%) | 0.0043 | |
| Ethnicity | ||||
| -Chinese | 12 (43%) | 22 (81%) | ||
| -South Asian | 9 (32%) | 1 (4%) | 0.0063 | |
| -Other | 7 (25%) | 4 (15%) | ||
| Charlson comorbidity index | 0 (0-1) | 0 (0-1) | 0.87 | |
| -Diabetes | 11 (39%) | 8 (30%) | 0.57 | |
| -Hypertension | 16 (57%) | 17 (63%) | 0.78 | |
| Days from symptom onset to desaturation | 8 (5-9) | 8 (6-9) | 0.93 | |
| Other experimental therapy | ||||
| -Anti-viral† | 4 (14%) | 18 (67%) | <0.0001 | |
| -Immunomodulator‡ | 4 (14%) | 4 (15%) | 1.00 | |
| Responders (n=21) | Non-responders (n=6) | – | – | |
| Doses (Interquartile range; median [days]) | 10 – 10; 10 | 7 – 10; 10 | – | – |
| Invasive mechanical ventilation | 7 (25%) | 10 (37%) | 0.39 | |
| -Duration (days, range) | - 6 (5-27) | - 8 (2-30) | ||
| Total duration supplemental oxygen (days) | 10.5 (8-18) | 9 (5-13) | 0.090 | |
| Duration hospital admission (days) | 21.5 (16-27) | 17 (13-21) | 0.10 | |
| Progression to intubation | 6 (22%) | 10 (37%) | 0.372 | |
| Death | 2 (7%) | 1 (4%) | 1.00 | |
AData is presented as median and inter-quartile range or n (%) unless otherwise specified. Continuous variables compared with Mann-Whitney, categorical with Fisher’s exact or Chi square as appropriate.
B†Lopinavir/ritonavir in 19, hydroxychloroquine in 5; ‡Corticosteroids in 2, interferon in 5, tocilizumab in 2 (note some patients received more than one agent).
CRemdesivir-treated group were treated with 200mg loading dose on day 1, followed by a maintenance dose administered daily thereafter.